Why the study?
The efficacy and safety of de-escalating from ticagrelor to clopidogrel after PCI may differ according to high bleeding risk status.
Does de-escalation from ticagrelor to clopidogrel reduce net adverse clinical events in patients with acute myocardial infarction after PCI regardless of high bleeding risk status?
Does de-escalation from ticagrelor to clopidogrel reduce net adverse clinical events in patients with acute myocardial infarction after PCI regardless of high bleeding risk status?
De-escalation from ticagrelor to clopidogrel reduces net adverse clinical events in stabilized AMI patients regardless of high bleeding risk status, with significant major bleeding reduction specifically in HBR patients.
Answers are grounded in this paper and cite their sources.
May support de-escalation in stabilized AMI post-PCI regardless of HBR; hypothesis-generating and requires randomized confirmation.
BACKGROUND: inhibition after percutaneous coronary intervention (PCI) may differ by high bleeding risk (HBR) status. AIMS: We investigated the efficacy and safety of de-escalation from ticagrelor to clopidogrel after PCI by HBR status. METHODS: This is a non-prespecified post hoc analysis of the TicAgrelor Versus CLOpidogrel in Stabilized Patients with Acute Myocardial Infarction (TALOS-AMI) trial. Net adverse clinical events (a composite of cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium [BARC] bleeding type 2, 3, or 5) at 1 year post-PCI were compared between the de-escalation (clopidogrel plus aspirin) and the active control (ticagrelor plus aspirin) groups by HBR status, as defined by the modification of the Academic Research Consortium (ARC) criteria. RESULTS: A total of 2,625 patients in the TALOS-AMI trial were analysed. Of these, 589 (22.4%) met the modified ARC-HBR criteria. The de-escalation group had lower primary endpoint rates than the control group in both HBR (hazard ratio [HR] 0.47, 95% confidence interval [CI]: 0.26-0.84) and non-HBR (HR 0.59, 95% CI: 0.41-0.84) patients. There were no differences in treatment effect for the primary endpoint regardless of HBR status (p for interaction=0.904). BARC bleeding type 3 or 5 was less common in the de-escalation than the control group among HBR patients only (HR 0.24, 95% CI: 0.07-0.84). CONCLUSIONS: inhibition on reducing haemorrhagic events was greater in patients with HBR.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: